Dose-dependent severe cutaneous reactions to imatinib

The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugurel, S, Hildenbrand, R, Dippel, E, Hochhaus, A, Schadendorf, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747559/
https://www.ncbi.nlm.nih.gov/pubmed/12698177
http://dx.doi.org/10.1038/sj.bjc.6600893
Descripción
Sumario:The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity.

Ejemplares similares